New Migraine Drugs Tied to Less Risk for Adverse Events
eMediNexus, 19 October 2021
remove_red_eye 562 Views
#Neurology #Pharmacist #Public Health
Coronavirus Live Count Map India
remove_red_eye 562 Views
COVID-19 Vaccine Updates
Coronavirus Protocols
#Neurology #Pharmacist #Public Health
According to a new systematic review and meta-analysis, new classes of antimigraine drugs appear to be effective and have improved tolerability among patients with chronic migraine.Investigators compared the outcomes for acute migraine management using lasmiditan (a 5-hydroxytryptamine [5HT]1F–receptor agonist), and gepants - rimegepant and ubrogepant (calcitonin gene–related peptide [CGRP] antagonists) - with standard triptan (selective 5-HT1B/1D–receptor agonist) treatment. T...
Create Account
Login Now
To read the complete article ,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
